p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas
Open Access
- 7 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (25) , 6826-6837
Abstract
Uncontrolled cell cycle entry, resulting from deregulated CDK-RB1-E2F pathway activity, is a crucial determinant of neuroblastoma cell malignancy. Here we identify neuroblastoma-suppressive functions of the p19-INK4d CDK inhibitor and uncover mechanisms of its repression in high-risk neuroblastomas. Reduced p19-INK4d expression was associated with poor event-free and overall survival and neuroblastoma risk factors including amplified MYCN in a set of 478 primary neuroblastomas. High MYCN expression repressed p19-INK4d mRNA and protein levels in different neuroblastoma cell models with conditional MYCN expression. MassARRAY and 450K methylation analyses of 105 primary neuroblastomas uncovered a differentially methylated region within p19-INK4d. Hypermethylation of this region was associated with reduced p19-INK4d expression. In accordance, p19-INK4d expression was activated upon treatment with the demethylating agent, 2′-deoxy-5-azacytidine, in neuroblastoma cell lines. Ectopic p19-INK4d expression decreased viability, clonogenicity and the capacity for anchorage-independent growth of neuroblastoma cells, and shifted the cell cycle towards the G1/0 phase. p19-INK4d also induced neurite-like processes and markers of neuronal differentiation. Moreover, neuroblastoma cell differentiation, induced by all-trans retinoic acid or NGF-NTRK1-signaling, activated p19-INK4d expression. Our findings pinpoint p19-INK4d as a neuroblastoma suppressor and provide evidence for MYCN-mediated repression and for epigenetic silencing of p19-INK4d by DNA hypermethylation in high-risk neuroblastomas.Keywords
This publication has 48 references indexed in Scilit:
- Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemiaNature Genetics, 2012
- Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkersGenome Biology, 2012
- IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation dataBioinformatics, 2012
- EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1, CLU, RUNX3, and NGFRCancer Research, 2012
- Identification of epigenetically regulated genes that predict patient outcome in neuroblastomaBMC Cancer, 2011
- Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patientsThe Pharmacogenomics Journal, 2010
- Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomasGenome Biology, 2008
- Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissuesGenome Biology, 2008
- High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A geneBMC Genomics, 2008
- Cancer Cell CyclesScience, 1996